New Mechanisms of Action


Our use of large-scale gene knockout technology has enabled us to identify more than 100 genetically-validated drug targets and our small molecule chemistry platform has yielded a significant pipeline of preclinical and clinical drug development programs. All of our drug candidates are new molecular entities discovered and developed internally by our dedicated drug discovery teams.

We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to less prevalent conditions, such as carcinoid syndrome, an orphan cancer indication with few treatment options.

The chart below provides an overview of our pipeline of drug candidates currently undergoing clinical testing.*

*The safety and efficacy of these drug candidates has not yet been evaluated by any regulatory authorities for the indications described.